Search research articles
Contact Us
Filters
Showing results (1-10 of 89) with videos related to
Page
of 9
Sort By:
Biological & Pharmaceutical Bulletin
|
January 6, 2009
Involvement of P-glycoprotein and multidrug resistance associated protein 1 on the transepithelial transport of a mercaptoacetamide-based histone-deacetylase inhibitor in Caco-2 cells
Zacharoula Konsoula, Mira Jung
International Journal of Pharmaceutics
|
June 20, 2008
In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors
Roula Konsoula, Mira Jung
The Journal of Biological Chemistry
|
March 21, 2007
The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation
Sung A Lee, Mira Jung
Chemistry & Biodiversity
|
December 29, 2006
Rational design and development of radiation-sensitizing histone deacetylase inhibitors
Mira Jung, Alan Kozikowski, Anatoly Dritschilo
Basic Research in Cardiology
|
December 8, 2018
Inflammatory cells and their non-coding RNAs as targets for treating myocardial infarction
Mira Jung, Michael Dodsworth, Thomas Thum
Current Topics in Medicinal Chemistry
|
April 10, 2009
Assays for histone deacetylases
Alexander-Thomas Hauser, Mira Jung, Manfred Jung
Molecular Cancer Therapeutics
|
October 1, 2009
Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors
Zacharoula Konsoula, Hong Cao, Alfredo Velena, et al.
Radiation Research
|
May 27, 2004
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors
Yin Zhang, Manfred Jung, Anatoly Dritschilo, et al.
Metalloproteinases in Medicine
|
July 5, 2016
Using the laws of thermodynamics to understand how matrix metalloproteinases coordinate the myocardial response to injury
Rugmani Padmanabhan Iyer, Mira Jung, Merry L Lindsey
Plos One
|
July 15, 2024
Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth
Mira Jung, Nicole Nicholas, Scott Grindrod, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 89) with videos related to
Sort By:
Page
of 9
Biological & Pharmaceutical Bulletin
|
January 6, 2009
Involvement of P-glycoprotein and multidrug resistance associated protein 1 on the transepithelial transport of a mercaptoacetamide-based histone-deacetylase inhibitor in Caco-2 cells
Zacharoula Konsoula, Mira Jung
International Journal of Pharmaceutics
|
June 20, 2008
In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors
Roula Konsoula, Mira Jung
The Journal of Biological Chemistry
|
March 21, 2007
The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation
Sung A Lee, Mira Jung
Chemistry & Biodiversity
|
December 29, 2006
Rational design and development of radiation-sensitizing histone deacetylase inhibitors
Mira Jung, Alan Kozikowski, Anatoly Dritschilo
Basic Research in Cardiology
|
December 8, 2018
Inflammatory cells and their non-coding RNAs as targets for treating myocardial infarction
Mira Jung, Michael Dodsworth, Thomas Thum
Current Topics in Medicinal Chemistry
|
April 10, 2009
Assays for histone deacetylases
Alexander-Thomas Hauser, Mira Jung, Manfred Jung
Molecular Cancer Therapeutics
|
October 1, 2009
Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors
Zacharoula Konsoula, Hong Cao, Alfredo Velena, et al.
Radiation Research
|
May 27, 2004
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors
Yin Zhang, Manfred Jung, Anatoly Dritschilo, et al.
Metalloproteinases in Medicine
|
July 5, 2016
Using the laws of thermodynamics to understand how matrix metalloproteinases coordinate the myocardial response to injury
Rugmani Padmanabhan Iyer, Mira Jung, Merry L Lindsey
Plos One
|
July 15, 2024
Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth
Mira Jung, Nicole Nicholas, Scott Grindrod, et al.
Page
of 9